In this webinar, you will learn:
- How to select the appropriate bispecific antibody format based on your target and functional intent.
- How to apply the various manufacturing and protein engineering approaches to overcome bispecific complexity.
- How high-confidence monoclonal antibody sequencing enables reproducible bispecific design.
Building Bispecific Antibodies with Confidence
Bispecific antibodies offer powerful new therapeutic possibilities—but their complexity demands sequence certainty, thoughtful design, and robust manufacturing strategies. In this webinar, we explore how successful bispecific development starts with high-confidence, reproducible antibody sequence determination of individual monoclonal antibodies followed by deliberate assembly into the most appropriate bispecific formats for each therapeutic application.
Learn how mode of action, target geometry, and valency directly influence antibody design decisions, and how these functional requirements guide format selection from the earliest stages. We will also examine scalable manufacturing strategies, spanning molecular biology, cell culture expression, and downstream processing, supported by in silico polishing prediction tools to help manage the inherent complexity of bispecific molecules.
Finally, the webinar demonstrates how early prototypes are efficiently transitioned into optimized lead candidates, highlighting protein engineering approaches that improve yield, stability, and overall developability, as well as show how sequencing technologies can confirm bispecific assembly.
Whether you are developing your first bispecific or optimizing an advanced pipeline, this session provides practical insights to help drive smarter design choices and accelerate progress toward the clinic.
Speaker Bios
Stefan R. Schmidt, PhD, MBA
Dr. Stefan R. Schmidt MBA, is currently CEO at evitria AG, a company dedicated to antibody discovery services in Zürich after leading operations at BioAtrium AG, a joint venture of Lonza and Sanofi in Visp, Switzerland as COO. Previously he held the position as CSO and other senior executive roles at Rentschler Biopharma, Germany with overall responsibilities for biologics development and manufacturing. Before that, he was CSO at ERA Biotech in Barcelona, Spain, directing the company’s R&D efforts based on fusion proteins. Prior to that, he worked at AstraZeneca in Sweden where he led the unit of Protein Sciences within Global Protein Science & Supply as Associate Director. He started his leadership career more than 25 years ago at Biotech companies in Munich, Germany where he built up protein biochemistry teams for Connex and GPC-Biotech. He holds a PhD in Biochemistry from the Julius Maximilians University in Wuerzburg, Germany and an MBA from the University in Gävle, Sweden.
Kathleen Gorospe
As the first member of Rapid Novor’s bioinformatics team, Kathleen has worked on and overseen the completion of over 10,000 antibody sequencing projects. With a background in health and biomedical sciences, as well as 7+ years of experience in de novo protein sequencing, she continues to apply her technical skills to solve sequencing challenges for antibody discovery and clinical diagnostics.